An Open-label, Multi-center, Non-randomized Phase Ib Study to Investigate the Safety, Efficacy, and Pharmacokinetics of BAY 73-4506 "Regorafenib", Administered in Combination With Pemetrexed and Cisplatin in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer.

Trial Profile

An Open-label, Multi-center, Non-randomized Phase Ib Study to Investigate the Safety, Efficacy, and Pharmacokinetics of BAY 73-4506 "Regorafenib", Administered in Combination With Pemetrexed and Cisplatin in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 11 Sep 2014

At a glance

  • Drugs Regorafenib (Primary) ; Cisplatin; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Biomarker; Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 24 Jun 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 23 Apr 2012 Planned end date changed from 1 Jul 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
    • 19 Mar 2012 Actual patient number (9) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top